Niox Group

Niox Group OCF Margin

The Operating Cash Flow Margin of Niox Group (NIOX.L) as of Nov 2, 2026 is 32.44 %. In the previous year, Operating Cash Flow Margin was 41.15 % — a change of -21.15% (lower).

OCF Margin

32.44 %

YoY

-21.15%

Last updated:

Operating Cash Flow Margin of Niox Group is 2025 32.44 % . Operating Cash Flow Margin of Niox Group was 2024 41.15 % . It decreases by -21.15% lower compared to the previous year.

The Niox Group OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
-84.06 GBP
Jan 1, 2019
-72.54 GBP
Jan 1, 2020
-100.00 GBP
Jan 1, 2021
5.02 GBP
Jan 1, 2022
21.41 GBP
Jan 1, 2023
31.52 GBP
Jan 1, 2024
41.15 GBP
Jan 1, 2025
32.44 GBP
The Niox Group OCF Margin history
YEAROCF MarginYoY
32.44 %-21.15%
41.15 %+30.54%
31.52 %+47.26%
21.41 %+326.59%
5.02 %-105.02%
-100.00 %+37.85%
-72.54 %-13.70%
-84.06 %-32.43%
-124.41 %-49.32%
-245.45 %-52.49%
-516.67 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Niox Group Stock analysis

What does Niox Group do? Circassia Group plc is a British biotechnology company specializing in the development of therapies for respiratory diseases. The company was founded in 2006 and is headquartered in Oxford. Circassia was founded by Steve Harris, who previously worked for the biopharmaceutical company Xenova Group plc. In its early years, the company focused on research and development of therapies for allergies and asthma. In 2014, Circassia went public on the London Stock Exchange. The company has developed an innovative business model that focuses on using its proprietary technology platform to identify novel therapy candidates. It works closely with pharmaceutical companies and other partners to accelerate the development of its therapy products and license its technology platform. Circassia's main focus is on developing therapies for respiratory diseases, particularly allergic asthma and chronic obstructive pulmonary disease (COPD). It has a range of products currently in various stages of clinical development. One of its leading products is NIOX VERO, a diagnostic device used to measure inflammation in the airways and improve the diagnosis of patients with asthma or COPD. Circassia also has a promising pipeline of therapy candidates, including Flutiform® (fluticasone propionate/formoterol fumarate), an inhaled medication for the treatment of asthma developed in collaboration with Japanese pharmaceutical company Kyorin. Additionally, the company has developed two novel drugs in the field of allergic rhinoconjunctivitis, one of which is currently being tested in phase III studies, while the other is nearing completion of phase II development. In conclusion, Circassia has established itself as an innovative biotechnology company focused on the development of therapies for respiratory diseases. It has a promising pipeline of therapy candidates at various stages of clinical development. The Circassia business model is based on utilizing its proprietary technology platform to identify and develop novel therapy candidates. Niox Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Niox Group stock

Operating Cash Flow Margin of Niox Group is 32.44 % in 2025.

Operating Cash Flow Margin of Niox Group changed from 41.15 % to 32.44 %, representing a -21.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Niox Group since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Niox Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Niox Group

All Key Metrics — Niox Group